Anti-Scl-70 antibodies

Anti-Scl-70 (also called anti-topoisomerase I after the type I topoisomerase target[1]) is an anti-topoisomerase antibody-type of anti-nuclear autoantibodies, seen mainly in diffuse systemic scleroderma (with a sensitivity of 28–70%), but is also seen in 10–18% of cases of the more limited form of systemic scleroderma called CREST syndrome.[2] Anti Scl-70 antibodies are associated with more severe scleroderma disease.[3]

The etymology of scl-70 consists of an abbreviation of scleroderma and a 70 kD extractable immunoreactive fragment that can be obtained from the otherwise larger (100–105 kD) target topoisomerase antigen (called the SCL-70 Antigen) of the antibodies.[4]

References

  1. ↑ Guldner HH, Szostecki C, Vosberg HP, Lakomek HJ, Penner E, Bautz FA (1986). "Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I". Chromosoma. 94 (2): 132–8. PMID 2428564. doi:10.1007/BF00286991.
  2. ↑ Table 5-9 in: Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson (2007). Robbins Basic Pathology. Philadelphia: Saunders. ISBN 1-4160-2973-7. 8th edition.
  3. ↑ de Rooij DJ, Van de Putte LB, Habets WJ, Van Venrooij WJ (1989). "Marker antibodies in scleroderma and polymyositis: clinical associations". Clin. Rheumatol. 8 (2): 231–7. PMID 2547546. doi:10.1007/BF02030079.
  4. ↑ Product Name: SCL-70 Antigen at ImmunoVision.com, retrieved April 2011
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.